These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 19038534)

  • 1. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
    Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
    J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
    Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
    Weiden PJ; Citrome L; Alva G; Brams M; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Pestreich L; Hochfeld M; Winseck A
    Schizophr Res; 2014 Mar; 153(1-3):160-8. PubMed ID: 24529610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
    Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
    Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
    Koch MT; Carlson HE; Kazimi MM; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2023 Sep; 62(9):1021-1050. PubMed ID: 36931560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
    Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
    Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
    BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
    Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
    J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
    Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
    Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A
    Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.